# PURPOSE 1 interim analysis: twice-yearly lenacapavir showed 100% efficacy for PrEP in cisgender women

Date: 2024

_No public text on this fact yet._

## Drivers

- HIV/AIDS global response: https://factrail.ai/drivers/hiv-aids-response

## Sources

_Sources are listed on the canonical page._

## Methodology

https://factrail.ai/methodology

Canonical: https://factrail.ai/facts/purpose1-lenacapavir-prep-100-efficacy-2024